PubMed:9920778
Annnotations
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-174 | Sentence | denotes | Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. |
| TextSentencer_T2 | 175-285 | Sentence | denotes | The human glucocorticoid receptor (GR) is expressed as two alternatively spliced isoforms, GRalpha and GRbeta. |
| TextSentencer_T3 | 286-472 | Sentence | denotes | Whereas GRalpha is a hormone-activated transcription factor, GRbeta does not bind glucocorticoids (GCs), is transcriptionally inactive, and is a potential inhibitor of activated GRalpha. |
| TextSentencer_T4 | 473-576 | Sentence | denotes | Differential expression of GR isoforms may play a role in generalized or tissue-specific GC resistance. |
| TextSentencer_T5 | 577-720 | Sentence | denotes | GCs induce apoptosis in neoplastic lymphoid cells; and, defective apoptosis is implicated in the genesis of chronic lymphocytic leukemia (CLL). |
| TextSentencer_T6 | 721-781 | Sentence | denotes | We studied a patient with generalized GC resistance and CLL. |
| TextSentencer_T7 | 782-959 | Sentence | denotes | GR number in the patient's transformed lymphocytes was approximately one half that of control cells with a approximately 10-fold reduction in binding affinity for dexamethasone. |
| TextSentencer_T8 | 960-1070 | Sentence | denotes | In vitro apoptosis induction in CLL cells was delayed in response to GCs, but not to other apoptosis inducers. |
| TextSentencer_T9 | 1071-1267 | Sentence | denotes | Sequencing of the GR cDNA and gene including the 2.3-kb coding region, the intron/exon junctions, the known 5'-regulatory region, and approximately 300 bp of the 3'-region revealed no alterations. |
| TextSentencer_T10 | 1268-1497 | Sentence | denotes | Western blot with an N-terminal antibody showed normal levels of immunoreactive GR, but quantitative analysis with isoform-specific C-terminal antibodies revealed a markedly reduced GRalpha expression, and high GRbeta expression. |
| TextSentencer_T11 | 1498-1676 | Sentence | denotes | These findings indicate that imbalanced expression of the GR isoforms may be a mechanism of GC resistance, and may have implications for tumorigenesis by enhancing cell survival. |
| T1 | 0-174 | Sentence | denotes | Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. |
| T2 | 175-285 | Sentence | denotes | The human glucocorticoid receptor (GR) is expressed as two alternatively spliced isoforms, GRalpha and GRbeta. |
| T3 | 286-472 | Sentence | denotes | Whereas GRalpha is a hormone-activated transcription factor, GRbeta does not bind glucocorticoids (GCs), is transcriptionally inactive, and is a potential inhibitor of activated GRalpha. |
| T4 | 473-576 | Sentence | denotes | Differential expression of GR isoforms may play a role in generalized or tissue-specific GC resistance. |
| T5 | 577-720 | Sentence | denotes | GCs induce apoptosis in neoplastic lymphoid cells; and, defective apoptosis is implicated in the genesis of chronic lymphocytic leukemia (CLL). |
| T6 | 721-781 | Sentence | denotes | We studied a patient with generalized GC resistance and CLL. |
| T7 | 782-959 | Sentence | denotes | GR number in the patient's transformed lymphocytes was approximately one half that of control cells with a approximately 10-fold reduction in binding affinity for dexamethasone. |
| T8 | 960-1070 | Sentence | denotes | In vitro apoptosis induction in CLL cells was delayed in response to GCs, but not to other apoptosis inducers. |
| T9 | 1071-1267 | Sentence | denotes | Sequencing of the GR cDNA and gene including the 2.3-kb coding region, the intron/exon junctions, the known 5'-regulatory region, and approximately 300 bp of the 3'-region revealed no alterations. |
| T10 | 1268-1497 | Sentence | denotes | Western blot with an N-terminal antibody showed normal levels of immunoreactive GR, but quantitative analysis with isoform-specific C-terminal antibodies revealed a markedly reduced GRalpha expression, and high GRbeta expression. |
| T11 | 1498-1676 | Sentence | denotes | These findings indicate that imbalanced expression of the GR isoforms may be a mechanism of GC resistance, and may have implications for tumorigenesis by enhancing cell survival. |
DisGeNET
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T0 | 1556-1558 | gene:2908 | denotes | GR |
| T1 | 1635-1648 | disease:C0596263 | denotes | tumorigenesis |
| R1 | T0 | T1 | associated_with | GR,tumorigenesis |
jnlpba-st-training
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 29-61 | protein | denotes | glucocorticoid receptor isoforms |
| T2 | 65-85 | cell_type | denotes | cultured lymphocytes |
| T3 | 179-208 | protein | denotes | human glucocorticoid receptor |
| T4 | 210-212 | protein | denotes | GR |
| T5 | 266-273 | protein | denotes | GRalpha |
| T6 | 278-284 | protein | denotes | GRbeta |
| T7 | 294-301 | protein | denotes | GRalpha |
| T8 | 325-345 | protein | denotes | transcription factor |
| T9 | 347-353 | protein | denotes | GRbeta |
| T10 | 464-471 | protein | denotes | GRalpha |
| T11 | 500-511 | protein | denotes | GR isoforms |
| T12 | 601-626 | cell_type | denotes | neoplastic lymphoid cells |
| T13 | 809-832 | cell_line | denotes | transformed lymphocytes |
| T14 | 992-1001 | cell_line | denotes | CLL cells |
| T15 | 1089-1096 | DNA | denotes | GR cDNA |
| T16 | 1179-1199 | DNA | denotes | 5'-regulatory region |
| T17 | 1233-1242 | DNA | denotes | 3'-region |
| T18 | 1333-1350 | protein | denotes | immunoreactive GR |
| T19 | 1400-1421 | protein | denotes | C-terminal antibodies |
| T20 | 1450-1457 | protein | denotes | GRalpha |
| T21 | 1479-1485 | protein | denotes | GRbeta |
| T22 | 1556-1567 | protein | denotes | GR isoforms |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 9920778-0#29#52#gene2908 | 29-52 | gene2908 | denotes | glucocorticoid receptor |
| 9920778-0#115#140#diseaseC1841972 | 115-140 | diseaseC1841972 | denotes | glucocorticoid resistance |
| 29#52#gene2908115#140#diseaseC1841972 | 9920778-0#29#52#gene2908 | 9920778-0#115#140#diseaseC1841972 | associated_with | glucocorticoid receptor,glucocorticoid resistance |
pubmed-sentences-benchmark
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| S1 | 0-174 | Sentence | denotes | Imbalanced expression of the glucocorticoid receptor isoforms in cultured lymphocytes from a patient with systemic glucocorticoid resistance and chronic lymphocytic leukemia. |
| S2 | 175-285 | Sentence | denotes | The human glucocorticoid receptor (GR) is expressed as two alternatively spliced isoforms, GRalpha and GRbeta. |
| S3 | 286-472 | Sentence | denotes | Whereas GRalpha is a hormone-activated transcription factor, GRbeta does not bind glucocorticoids (GCs), is transcriptionally inactive, and is a potential inhibitor of activated GRalpha. |
| S4 | 473-576 | Sentence | denotes | Differential expression of GR isoforms may play a role in generalized or tissue-specific GC resistance. |
| S5 | 577-720 | Sentence | denotes | GCs induce apoptosis in neoplastic lymphoid cells; and, defective apoptosis is implicated in the genesis of chronic lymphocytic leukemia (CLL). |
| S6 | 721-781 | Sentence | denotes | We studied a patient with generalized GC resistance and CLL. |
| S7 | 782-959 | Sentence | denotes | GR number in the patient's transformed lymphocytes was approximately one half that of control cells with a approximately 10-fold reduction in binding affinity for dexamethasone. |
| S8 | 960-1070 | Sentence | denotes | In vitro apoptosis induction in CLL cells was delayed in response to GCs, but not to other apoptosis inducers. |
| S9 | 1071-1267 | Sentence | denotes | Sequencing of the GR cDNA and gene including the 2.3-kb coding region, the intron/exon junctions, the known 5'-regulatory region, and approximately 300 bp of the 3'-region revealed no alterations. |
| S10 | 1268-1497 | Sentence | denotes | Western blot with an N-terminal antibody showed normal levels of immunoreactive GR, but quantitative analysis with isoform-specific C-terminal antibodies revealed a markedly reduced GRalpha expression, and high GRbeta expression. |
| S11 | 1498-1676 | Sentence | denotes | These findings indicate that imbalanced expression of the GR isoforms may be a mechanism of GC resistance, and may have implications for tumorigenesis by enhancing cell survival. |
genia-medco-coref
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| C1 | 25-61 | NP | denotes | the glucocorticoid receptor isoforms |
| C2 | 230-264 | NP | denotes | two alternatively spliced isoforms |
| C4 | 266-273 | NP | denotes | GRalpha |
| C5 | 278-284 | NP | denotes | GRbeta |
| C3 | 266-284 | NP | denotes | GRalpha and GRbeta |
| C6 | 294-301 | NP | denotes | GRalpha |
| C7 | 347-353 | NP | denotes | GRbeta |
| C8 | 368-389 | NP | denotes | glucocorticoids (GCs) |
| C9 | 500-511 | NP | denotes | GR isoforms |
| C10 | 577-580 | NP | denotes | GCs |
| C11 | 685-719 | NP | denotes | chronic lymphocytic leukemia (CLL) |
| C12 | 777-780 | NP | denotes | CLL |
| C13 | 782-791 | NP | denotes | GR number |
| C14 | 860-864 | NP | denotes | that |
| C15 | 1029-1032 | NP | denotes | GCs |
| C16 | 1552-1567 | NP | denotes | the GR isoforms |
| R1 | C2 | C1 | coref-ident | two alternatively spliced isoforms,the glucocorticoid receptor isoforms |
| R2 | C3 | C2 | coref-appos | GRalpha and GRbeta,two alternatively spliced isoforms |
| R3 | C6 | C4 | coref-ident | GRalpha,GRalpha |
| R4 | C7 | C5 | coref-ident | GRbeta,GRbeta |
| R5 | C9 | C2 | coref-ident | GR isoforms,two alternatively spliced isoforms |
| R6 | C10 | C8 | coref-ident | GCs,glucocorticoids (GCs) |
| R7 | C12 | C11 | coref-ident | CLL,chronic lymphocytic leukemia (CLL) |
| R8 | C14 | C13 | coref-relat | that,GR number |
| R9 | C15 | C10 | coref-ident | GCs,GCs |
| R10 | C16 | C9 | coref-ident | the GR isoforms,GR isoforms |
GENIAcorpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 29-61 | protein_family_or_group | denotes | glucocorticoid receptor isoforms |
| T2 | 65-85 | cell_type | denotes | cultured lymphocytes |
| T3 | 115-140 | other_name | denotes | glucocorticoid resistance |
| T4 | 145-173 | other_name | denotes | chronic lymphocytic leukemia |
| T5 | 179-208 | protein_family_or_group | denotes | human glucocorticoid receptor |
| T6 | 210-212 | protein_family_or_group | denotes | GR |
| T7 | 266-273 | protein_molecule | denotes | GRalpha |
| T8 | 278-284 | protein_molecule | denotes | GRbeta |
| T9 | 294-301 | protein_molecule | denotes | GRalpha |
| T10 | 325-345 | protein_family_or_group | denotes | transcription factor |
| T11 | 347-353 | protein_molecule | denotes | GRbeta |
| T12 | 368-383 | lipid | denotes | glucocorticoids |
| T13 | 385-388 | lipid | denotes | GCs |
| T14 | 394-420 | other_name | denotes | transcriptionally inactive |
| T15 | 464-471 | protein_molecule | denotes | GRalpha |
| T16 | 500-511 | protein_family_or_group | denotes | GR isoforms |
| T17 | 562-575 | other_name | denotes | GC resistance |
| T18 | 577-580 | lipid | denotes | GCs |
| T19 | 588-597 | other_name | denotes | apoptosis |
| T20 | 601-626 | cell_type | denotes | neoplastic lymphoid cells |
| T21 | 643-652 | other_name | denotes | apoptosis |
| T22 | 685-713 | other_name | denotes | chronic lymphocytic leukemia |
| T23 | 715-718 | other_name | denotes | CLL |
| T24 | 747-758 | other_name | denotes | generalized |
| T25 | 759-772 | other_name | denotes | GC resistance |
| T26 | 777-780 | other_name | denotes | CLL |
| T27 | 782-791 | other_name | denotes | GR number |
| T28 | 809-832 | cell_line | denotes | transformed lymphocytes |
| T29 | 945-958 | lipid | denotes | dexamethasone |
| T30 | 969-978 | other_name | denotes | apoptosis |
| T31 | 992-995 | other_name | denotes | CLL |
| T32 | 1029-1032 | lipid | denotes | GCs |
| T33 | 1051-1060 | other_name | denotes | apoptosis |
| T34 | 1089-1096 | DNA_family_or_group | denotes | GR cDNA |
| T35 | 1179-1199 | DNA_domain_or_region | denotes | 5'-regulatory region |
| T36 | 1233-1242 | DNA_domain_or_region | denotes | 3'-region |
| T37 | 1333-1350 | protein_family_or_group | denotes | immunoreactive GR |
| T38 | 1400-1421 | protein_family_or_group | denotes | C-terminal antibodies |
| T39 | 1450-1457 | protein_molecule | denotes | GRalpha |
| T40 | 1479-1485 | protein_molecule | denotes | GRbeta |
| T41 | 1527-1548 | other_name | denotes | imbalanced expression |
| T42 | 1556-1567 | protein_family_or_group | denotes | GR isoforms |
| T43 | 1590-1603 | other_name | denotes | GC resistance |
| T44 | 1635-1648 | other_name | denotes | tumorigenesis |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 546-552 | http://purl.obolibrary.org/obo/UBERON_0000479 | denotes | tissue |
PubCasesHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TI1 | 165-173 | HP:0001909 | denotes | leukemia |
| AB1 | 705-713 | HP:0001909 | denotes | leukemia |
UBERON-AE
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 546-552 | http://purl.obolibrary.org/obo/UBERON_0000479 | denotes | tissue |
PubCasesORDO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TI1 | 115-140 | ORDO:786 | denotes | glucocorticoid resistance |